Semax vs Selank — Two Russian Nootropic Peptides, Different Mechanisms

Russian peptide pharmacology produced two flagship nootropic compounds in the late 20th century — Semax and Selank — both 7-amino-acid synthetic peptides, both with established Russian clinical use, both routinely confused in Western peptide-research discussion. The two are not interchangeable. Different parent peptides, different molecular mechanisms, different research endpoints. This is the comparison for UAE peptide researchers running cognitive or anxiolytic protocols.

1. The Russian peptide-pharmacology tradition

Both peptides emerged from the Soviet/Russian neuropeptide research program centred at the Institute of Molecular Genetics (Moscow) and the Institute of Drug Research. The design philosophy was distinctive: take a known endogenous peptide (ACTH, tuftsin) with central nervous system activity, identify the active fragment, then stabilise it against protease degradation by amino acid substitutions and N/C-terminal modifications.

Both compounds went through Russian phase I-III equivalents and were registered for clinical use in Russia (Semax for cognitive indications and stroke recovery; Selank for anxiety). Neither was developed in Western pharmaceutical markets, which is why they remain research-grade material in most jurisdictions outside Russia.

2. The molecular biology — different parents

Both peptides retain a Pro-Gly-Pro C-terminal sequence which makes them resistant to amino-peptidase degradation — a Russian peptide-stabilisation signature seen across the broader peptide-research program.

3. The mechanisms — fundamentally different

Semax mechanism

• BDNF (brain-derived neurotrophic factor) upregulation — Dolotov 2006 J Neurochem showed Semax acutely raises BDNF mRNA in hippocampus and frontal cortex.
• NGF (nerve growth factor) upregulation — additional neurotrophic effect.
• Dopaminergic system modulation — Eremin 2005 showed enhanced dopamine release in prefrontal cortex.
• Melanocortin receptor activity — ACTH-derived, so retains some MC receptor binding (likely MC4R-related).
• Net effect: activating, focus-enhancing, neuroprotective.

Selank mechanism

• GABAergic potentiation — Kozlovskaya 2003 showed Selank facilitates GABA neurotransmission without acting as a classical benzodiazepine.
• Serotonergic modulation — Volkova 2016 showed serotonin metabolism effects in prefrontal cortex.
• Enkephalin pathway interaction — Kost 2001 showed Selank stabilises endogenous enkephalin levels.
• Immunomodulatory effects — tuftsin-derived, retains some immune-cell modulation.
• Net effect: calming, anxiolytic, without benzodiazepine-class sedation or dependence profile.

4. Side-by-side comparison

5. The published evidence base

Semax evidence highlights

• Dolotov 2006 (J Neurochem): BDNF/NGF upregulation in hippocampus and frontal cortex
• Medvedeva 2014 (BMC Genomics): Genome-wide expression profiling — broad neurotrophic and synaptogenesis-related gene upregulation
• Gusev 2005: Stroke recovery clinical trial — improved neurological outcome at 30 days
• Ashmarin 1995: Foundational pharmacology paper
• Manchenko 2010: Anxiolytic-like effects observed in some preclinical paradigms (overlap with Selank, but smaller)

Selank evidence highlights

• Kost 2001: Enkephalin stabilisation mechanism
• Kozlovskaya 2003: GABAergic mechanism characterisation
• Volkova 2016: Serotonergic and BDNF effects
• Zozulia 2008: Clinical anxiolytic trial — comparable to benzodiazepine effect without sedation
• Mahmoudi 2018: Anti-inflammatory peripheral effects

6. The dosing — both peptides converge on similar routes/doses

7. Stackable — and the case for stacking

The non-overlapping mechanisms make the Semax + Selank stack mechanistically coherent. Researchers running combined protocols typically use:

• Semax morning + midday — for activating/focus effect during work hours
• Selank evening — for anxiolytic effect during decompression / pre-sleep

The combination produces a "wide window of operation" — focused during the day, calmer in the evening — without the trade-offs that single-mechanism interventions (caffeine, stimulants, benzodiazepines) impose.

There are no published combination trials. The stack is mechanism-based researcher protocol synthesis.

8. The route — intranasal as the published default

The Russian clinical formulations are intranasal (Semax 0.1%, Selank 0.15%). Intranasal delivery bypasses gastric peptidase breakdown and provides rapid CNS access via the olfactory nerve / cribriform plate pathway. The published pharmacokinetic data shows intranasal peptide concentrations in CSF within 15-30 minutes — much faster than systemic distribution from SC injection.

SC injection works (the peptides distribute systemically and reach the CNS via blood-brain barrier transport) but for nootropic research, intranasal is the published research route. The full intranasal protocol breakdown for Semax sits in our Semax dosing protocol writeup.

9. The which-one-when decision

Choose Semax if you're researching:

• Cognitive performance, focus, attention endpoints
• Neuroprotection (stroke research, neurodegeneration)
• BDNF / neurotrophic signalling
• ADHD-adjacent or pediatric cognitive research (Russian indication)
• Recovery from cognitive fatigue

Choose Selank if you're researching:

• Anxiety research, stress-response modulation
• Sleep quality (pre-sleep anxiolysis)
• GABAergic mechanisms without benzodiazepine pharmacology
• Serotonin pathway research

Stack both if:

• You want a combined activating/calming research protocol
• Your research question spans both endpoints (e.g., cognitive performance under stress)

10. The safety record

Both peptides have multi-decade Russian clinical-use records with benign safety profiles. The published adverse event spectrum is limited to:

• Nasal irritation (intranasal route)
• Headache (uncommon, transient)
• Occasional sleep changes (vivid dreams reported anecdotally with both)

Neither peptide has shown abuse potential, dependence syndrome, or significant withdrawal in the Russian clinical record.

11. UAE supply context

Semax is reliably stocked at REVIVE LAB UAE in 10 mg HPLC-verified lyophilised vials with lot-level COA. Selank availability varies by lot — research-grade Selank has a smaller global supply chain than Semax.

Semax UAE ships same-day on Dubai orders before 3 PM, 24 hours nationwide. WhatsApp +971 58 574 3100 to check current Selank stock.

12. The summary

• Semax (ACTH-derived) → BDNF + dopamine → focus, attention, neuroprotection research.
• Selank (tuftsin-derived) → GABA + serotonin → anxiolysis, stress-response research.
• Both heptapeptides with Pro-Gly-Pro C-terminal stabilisation.
• Both intranasal route at 1 mg/mL (matches Russian 0.1% clinical formulation).
• Both 250-1000+ μg/day, split into 2-3 daily doses.
• Mechanisms non-overlapping — stackable for combined activating/calming research.
• REVIVE LAB UAE stocks Semax HPLC-verified in 10 mg vials.